Clinical Trials Logo

Clinical Trial Summary

Early diagnosis of pregnancy with its localization and evolution has always been one of the major objectives of gynecology and obstetrics, even more so in Artificial Reproductive Technology (ART) centers. The pivotal test is the βHCG assay. Various protocols have been proposed over the years, including single assessment and serial assays. Several studies in the past years have tried to define a cut-off predictive of a successful pregnancy. Abnormal levels of βHCG are associated with biochemical pregnancies, non-viable pregnancies and ectopic pregnancies (EP). The efficacy of a single serum βHCG test to predict EP is low and a significant amount of time and resources are spent diagnosing it. In recent studies, better sensitivity was obtained from the ratio of two successive time points of βHCG concentration, with better specificity instead from regression models. These proposed models however lack validation and require further improvement.


Clinical Trial Description

Fertility clinics follow different protocols for the measurement of βHCG. Typically the initial serum measurement is performed 10-12 days after blastocyst transfer or 12-14 days after transfer at cleavage stage. Often a second serum measurement of hCG is performed at 48h since an increase of at least 50% is known to be a good predictor of ongoing pregnancy. The doubling time was first described in natural pregnancies where the rate of βHCG rise was reported to be at least 53% in two days, with a median of 50% increase at day 1 and 124% at day 2. Following the first detection and rise of serum βHCG, it is possible to predict earlier than with transvaginal ultrasound non-viable pregnancies, ectopic pregnancies, biochemical pregnancies and spontaneous abortion or reassure the couple when these values are representative of an ongoing pregnancy (OP). Conversely, however, many studies have found different thresholds of βHCG to be representative of OP, with many women under the cut-off value ending up having a normal pregnancy. The variability within the threshold expresses the need for a better biological marker or cut-off value. Implementing patient characteristics in a model to redefine and personalize the cut-off is necessary to improve pregnancy detection and management. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05305027
Study type Observational
Source Istituto Clinico Humanitas
Contact
Status Completed
Phase
Start date January 1, 2011
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03754621 - Upper Limit for TSH of First and Second Trimester Pregnancy in Turkey
Terminated NCT04454749 - Endometrial Compaction and Its Influence on Pregnancy Rate in Frozen Embryo Cycle Regimes
Completed NCT03743922 - The Effects of Vitamin D2 Supplement During Pregnancy N/A
Completed NCT03957200 - Assessing Gestational Age in First Trimester Pregnancies Using Ultrasound
Terminated NCT03954587 - What is the Optimal Cycle Regimen for Frozen- Thawed Embryo Transfer Cycles
Active, not recruiting NCT05492981 - Does an Educational Video for Aneuploidy Screening Improve Informed Choice Among Pregnant Women? N/A
Completed NCT02510209 - Evaluation of the Teen Outreach Program in Hennepin County, Minnesota N/A
Completed NCT03320226 - A Study of the Effect of Probiotics on Gastrointestinal Function During Pregnancy N/A
Completed NCT04321564 - Comparison of Beck Depression Score in Multipar and Nulliparous Women Who Have Gone Under Dilatation and Curettage
Recruiting NCT05870878 - Generation R Next - Optimaal Opgroeien N/A
Completed NCT04565873 - Thyroid Stimulating Hormone (TSH) Level Variations in Early Pregnancy
Completed NCT04182750 - Promoting Safe Medication Use in Pregnancy in the Era of Real-World Data - The SafeStart Study N/A
Completed NCT04714905 - Better Understanding the Metamorphosis of Pregnancy (BUMP)
Active, not recruiting NCT03461835 - Management of Pregnancies of Unknown Location (PUL) N/A
Recruiting NCT04797338 - Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders Phase 4
Completed NCT03513536 - The Effect of Scent on Pregnancy Induced Nausea, Vomiting, and Quality of Life N/A